



**CENTRO
NAZIONALE
SANGUE**



La domanda e la spesa dei medicinali plasmaderivati in Italia


Fabio Candura

Settore plasma e medicinali plasmaderivati

Centro nazionale sangue

L'utilizzo dei medicinali plasmaderivati in Italia

Istituto Superiore di Sanità - Roma, 12 maggio 2016



Indice

- Medicinali plasmaderivati oggetto di contolavorazione
- Altri medicinali plasmaderivati
- Spesa farmaceutica dei medicinali plasmaderivati e delle alternative terapeutiche di natura ricombinante







Medicinali plasmaderivati oggetto di conto-lavorazione



ALBUMINA


Domanda nazionale 2011-2014 e regionale 2014






ALBUMINA




Domanda nazionale 2011-2014 e regionale 2014






IMMUNOGLOBULINE POLIVALENTI a USO ENDOVENOSO

Domanda nazionale 2011-2014 e regionale 2014






IMMUNOGLOBULINE POLIVALENTI a USO SOTTOCUTANEO

Domanda nazionale 2011-2014 e regionale 2014


Domanda Totale 2014: **487.469 g**

Δ 2011 – 2014: **374.719 g (332%)**


Immunoglobuline SC: Domanda Totale (g) 2011-2014




Immunoglobuline IV + SC: Domanda Totale (g per mille pop) 2007-2014






Domanda totale 2014
8 g per mille abitanti






Antitrombina


Domanda nazionale 2011-2014 e regionale 2014






Fattore VIII


Domanda nazionale 2011-2014 e regionale 2014



Domanda totale 2014
58.616.850 UI


Δ 2011 – 2014
153.431.500 UI (+39%)






Fattore VIII

Domanda nazionale 2011-2014 e regionale 2014







Domanda totale 2014 (UI per capita): 9





Fattore VIII


Domanda nazionale 2011-2014 e regionale 2014






Fattore IX


Domanda nazionale 2011-2014 e regionale 2014



Domanda totale 2014
58.616.850 UI



Δ 2011 – 2014
+7.513.850 UI (+15%)






Fattore IX

Domanda nazionale 2011-2014 e regionale 2014







Fattore IX

Domanda nazionale 2011-2014 e regionale 2014


FIXpd: Domanda Totale (UI) 2011-2014




rFIX: Domanda Totale (UI) 2011-2014




Domanda totale (UI pro capite): 0,2



Domanda totale (UI pro capite): 0,8






Concentrati di complesso protrombinico

Domanda nazionale 2011-2014 e regionale 2014


Concentrati di complesso protrombinico 3 fattori:

Domanda totale (UI) 2011-2014




Concentrati di complesso protrombinico 4 fattori:


Domanda totale (UI) 2011-2014




Domanda totale 2014 (UI pro capite): **0,6**




Domanda totale 2014 (UI per mille abitanti): **70**










Altri medicinali plasmaderivati



FVII attivato, ricombinante & Complesso protrombinico attivato


Domanda nazionale 2011-2014 e regionale 2014






Trend della domanda Altri medicinali plasmaderivati


Emostatici locali: Domanda Totale (ml)



Emostatici locali: Domanda Totale (sp)




Fattore VII: Domanda Totale (UI)






Trend della domanda Altri medicinali plasmaderivati


Immunoglobuline Anti-D (Rh): Domanda Totale (UI)



Immunoglobuline CMV: Domanda Totale (UI)




Immunoglobuline Antitetano: Domanda Totale (UI)








Trend della domanda Altri medicinali plasmaderivati

Immunoglobuline Antiepatite B SC: Domanda Totale (UI)




Immunoglobuline Antiepatite B EV: Domanda Totale (UI)





Spesa farmaceutica dei medicinali plasmaderivati e delle alternative terapeutiche di natura ricombinante




La spesa farmaceutica

- MPD compresi nelle convenzioni tra le Regioni e l'azienda Kedrion acquistati per la quota di fabbisogno non coperta dalla distribuzione del conto-lavorazione (albumina, IVIG, FVIIIpd, FIXpd, CCP3 e AT);
- medicinali ricombinanti utilizzati nel trattamento di disordini congeniti della coagulazione (rFVIIa, rFVIII e rFIX);
- altri MPD, non attualmente inseriti nei contratti di conto-lavorazione





La spesa farmaceutica 2011 - 2014







La spesa farmaceutica





La spesa farmaceutica







La spesa farmaceutica 2014 – Totale


2014: **126.808.095 euro**

2011 vs 2014: **+5,6%**






La spesa farmaceutica 2014 – Albumina




2014: **33.643.712 euro**
2011 vs 2014: **-26%**







La spesa farmaceutica 2014 – IVIG




2014: **44.535.721 euro**
2011 vs 2014: **+15%**







La spesa farmaceutica 2014 – FVIIIpd




2014: **38.306.745 euro**
2011 vs 2014: **+72%**







La spesa farmaceutica 2014 – AT



2014: **8.195.993 euro**
2011 vs 2014: **-28%**






La spesa farmaceutica

- MPD compresi nelle convenzioni tra le Regioni e l'azienda Kedrion acquistati per la quota di fabbisogno non coperta dalla distribuzione del conto-lavorazione (albumina, IVIG, FVIIIpd, FIXpd, CCP3 e AT);
- medicinali ricombinanti utilizzati nel trattamento di disordini congeniti della coagulazione (rFVIIa, rFVIII e rFIX);
- altri MPD, non attualmente inseriti nei contratti di conto-lavorazione





La spesa farmaceutica 2011 - 2014






La spesa farmaceutica







La spesa farmaceutica 2014 – rFVIII




2014: **282.714.637 euro**
2011 vs 2014: **+29%**






La spesa farmaceutica

- MPD compresi nelle convenzioni tra le Regioni e l'azienda Kedrion acquistati per la quota di fabbisogno non coperta dalla distribuzione del conto-lavorazione (albumina, IVIG, FVIIIpd, FIXpd, CCP3 e AT);
- medicinali ricombinanti utilizzati nel trattamento di disordini congeniti della coagulazione (rFVIIa, rFVIII e rFIX);
- altri MPD, non attualmente inseriti nei contratti di conto-lavorazione





La spesa farmaceutica 2011 - 2014





La spesa farmaceutica





Ringraziamenti

Alberto Martinez Montero
Alessandra Mecozzi
Angus Young
Anna Ceccarelli
Lorenzo Castelli
Rosa Chianese
Annalisa Di Vito
Aurora Di Filippo
Baxalta SpA
Chiara Brutti
Claudia Biffoli
Cristiana Chelucci
Deanna Calteri
Elena, Eva & Margot
Enzo Catania
Franco e Simona del Bar
Gabriele Calizzani
Giancarlo Maria Liunbruno
Giovanna Antonini
Giuliano Grazzini
Giuseppe Marano
Ilaria Mazzetti
Jimmy Page
John Bonham
John Paul Jones
Kedrion SpA
Livia Cannata
Liviana Catalano
Lorella Lombardozi
Malcolm Young
Maria Grazia Chimenti
Massimiliano Benini
Pfizer Italia
Pierluigi Russo
Robert Plant
Robert Zimmerman
Samantha Profili
Sandra Salinetti
Simonetta Pupella
Stefania Vaglio
Vincenzo de Angelis

MONICA LANZONI